A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

The embattled diet brand said it is adding a compounded weight-loss drug in accordance with FDA rules and manufacturing ...

With the addition of compounded semaglutide [GLP-1], we are expanding our offering to include a clinical weight management ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

WHAT TO KNOW ABOUT GLP-1 SHORTAGES — It’s been a busy week in the diabetes and weight-loss drug world as Eli Lilly renews its push to shut down the compounding of its tirzepatide products and the ...

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...